The U.S. Food and Drug Administration (FDA) has classified a nationwide recall involving 3,648 bottles of fenofibrate, a prescription medication used to treat high cholesterol and triglyceride levels, after reported manufacturing deviations raised concerns about whether the affected product consistently met federal quality standards.
FDA Classifies Nationwide Fenofibrate Recall as Class II
The recall involves 100-count bottles of 200-milligram fenofibrate capsules manufactured by Ajanta Pharma Limited in India. According to the FDA, the voluntary nationwide recall began on May 8, 2026, and was later designated a Class II recall, the agency’s intermediate risk category.
A Class II designation means that exposure to or use of the affected product may cause temporary or medically reversible adverse health consequences, while the probability of serious health consequences is considered remote. This classification provides an important distinction: it does not automatically mean that every recalled bottle is defective or that every person who has taken the medication will experience an adverse reaction.
The recalled product can be identified by lot number PA02216 and carries an expiration date of December 2029. A total of 3,648 bottles are included in the recall.
Ajanta Pharmaceuticals, based in New Jersey, voluntarily initiated the recall after reported current good manufacturing practice deviations, commonly known as CGMP deviations. These federal manufacturing requirements are designed to ensure that medications consistently meet established standards for identity, strength, quality, and purity.
For patients who rely on fenofibrate to control lipid levels, the recall makes checking the exact product information particularly relevant. Patients should not assume that all fenofibrate products are affected, as the recall is tied to a specific strength, package size, manufacturer, and lot.
Credit: Canva
What the FDA Says About the Manufacturing Deviations
The FDA describes current good manufacturing practice regulations as a system of controls intended to help pharmaceutical manufacturers prevent contamination, product mix-ups, deviations, failures, and errors. Compliance is designed to ensure that drug products maintain their expected identity, strength, quality, and purity.
The recall notice cites CGMP deviations as the reason for the action. Based on the information reported, no specific contaminant or individual manufacturing defect was identified in the source article. The significance of the recall instead centers on deviations from processes intended to ensure consistent pharmaceutical quality.
That distinction matters when interpreting the scope of the action. A manufacturing deviation can trigger a recall even when there is no public evidence that every unit has caused harm. Federal oversight systems are designed to identify and remove products when quality controls may not have been followed as required.
The FDA’s Class II classification reflects its assessment of the potential health risk associated with the recalled medication. Under this category, adverse effects may be temporary or medically reversible, while serious consequences are considered unlikely.
Consumers should therefore rely on the specific identifying information attached to the recall rather than discontinuing medication solely because they take fenofibrate. The relevant product is a 200-milligram capsule supplied in bottles of 100, bearing lot PA02216 and an expiration date of 12/2029.
What Fenofibrate Does and Why Patients Take It
Fenofibrate is a prescription medication used to treat elevated levels of cholesterol and triglycerides in the blood. It belongs to a class of medicines known as fibrates and works differently from statins, another widely prescribed category of cholesterol-lowering drugs.
According to the Cleveland Clinic, fenofibrate works by decreasing levels of so-called bad cholesterol and fats while increasing good cholesterol in the blood. The medication may be prescribed as part of a broader treatment strategy that can also include dietary changes, exercise, weight management, and monitoring of blood lipid levels.
Fenofibrate is commonly used in patients with high triglycerides or certain forms of mixed dyslipidemia. Managing these blood fats can be an important component of reducing health risks associated with abnormal lipid levels.
The recalled capsules are a generic medication associated with the branded drug Lipofen. The recall does not apply to every fenofibrate prescription or every manufacturer producing the drug, based on the details cited in the recall report.
Because cholesterol medications are often taken continuously over long periods, abruptly stopping a prescribed treatment without medical guidance can create separate health concerns. Patients who discover that they possess an affected bottle should contact their pharmacist or healthcare professional for instructions about replacement medication and continued treatment.
How to Identify the Recalled Fenofibrate Bottles
Patients can determine whether their medication may be involved by checking several pieces of information printed on the prescription bottle or dispensing label. The affected product consists of fenofibrate 200-milligram capsules, packaged in 100-count bottles.
The recalled lot number is PA02216, and the listed expiration date is December 2029. The medication was manufactured by Ajanta Pharma Limited in India, while New Jersey-based Ajanta Pharmaceuticals initiated the voluntary recall.
Not every pharmacy label displays the original manufacturer’s lot number in an immediately obvious location. Patients who cannot determine whether their prescription came from the affected lot can contact the dispensing pharmacy, which may be able to verify the manufacturer and lot information through its inventory and dispensing records.
Consumers should avoid making assumptions based only on the medication name. Generic drugs can be manufactured by multiple companies, and recalls frequently apply only to particular lots, strengths, dosage forms, or package configurations.
Anyone with an affected product should seek guidance from a pharmacist or prescribing healthcare professional about the appropriate next steps. Medication should not be stopped or replaced without considering the patient’s individual treatment needs and professional medical advice.
Why a Class II Recall Matters for Patients
The FDA uses recall classifications to communicate the level of health risk associated with a defective or potentially defective product. Class I recalls represent situations in which exposure could cause serious adverse health consequences or death, while Class III recalls generally involve products unlikely to cause adverse health consequences.
A Class II recall, the category assigned to this fenofibrate action, falls between those two levels. It applies when use of or exposure to a product may cause temporary or medically reversible health consequences, or when the probability of serious adverse consequences is remote.
This classification helps provide context for patients who may be concerned after discovering that their medication is subject to a recall. The designation indicates a genuine quality or safety issue that warrants action, but it does not suggest that severe harm is expected in most people who may have used the affected product.
The scope of the recall—3,648 bottles distributed nationwide—also means that the number of individual capsules involved is considerably larger, since each bottle contains 100 capsules. Still, the recall remains limited to the identified product configuration and lot.
For consumers, the most practical response is to verify the prescription details, contact the dispensing pharmacy if necessary, and follow professional instructions regarding replacement or continued treatment. Anyone experiencing unexpected symptoms or suspected adverse reactions should seek appropriate medical care.
What Patients Should Know Now
The recall underscores how pharmaceutical quality controls continue after medications enter commercial distribution. Manufacturing standards are intended to maintain consistency across every stage of drug production, and deviations from those standards can lead to voluntary recalls and subsequent FDA classification.
Patients taking fenofibrate 200-milligram capsules should check whether their medication matches lot PA02216, with an expiration date of 12/2029, and was supplied in the affected 100-count bottle configuration.
Those who cannot find the lot information should contact their pharmacist rather than assuming their prescription is included. The recall described here does not cover every fenofibrate product available in the United States.
The key concern is precise identification of the affected medication while maintaining continuity of medically necessary treatment. Patients with recalled medication should consult their pharmacist or healthcare professional for guidance tailored to their prescription and health needs.
